Skip to main content
Top
Published in: BMC Geriatrics 1/2022

Open Access 01-12-2022 | Opioids | Research

Prescription opioids among older adults: ten years of data across five countries

Authors: A. Hamina, A. E. Muller, T. Clausen, S. Skurtveit, M. Hesse, C. Tjagvad, B. Thylstrup, I. Odsbu, H. Zoega, H. L. Jónsdóttir, H. Taipale

Published in: BMC Geriatrics | Issue 1/2022

Login to get access

Abstract

Background

Opioid use has increased globally in the recent decade. Although pain remains a significant problem among older adults, susceptibility to opioid-related harms highlights the importance of careful opioid therapy monitoring on individual and societal levels. We aimed to describe the trends of prescription opioid utilisation among residents aged ≥65 in all Nordic countries during 2009–2018.

Methods

We conducted cross-sectional measurements of opioid utilisation in 2009–2018 from nationwide registers of dispensed drugs in Denmark, Finland, Iceland, Norway, and Sweden. The measures included annual opioid prevalence, defined daily doses (DDDs) per 1000 inhabitants per day (DIDs), and morphine milligram equivalents (MMEs) per user per day.

Results

From 2009 to 2018, an average of 808,584 of adults aged ≥65 used opioids yearly in all five countries; an average annual prevalence of 17.0%. During this time period, the prevalence decreased in Denmark, Norway, and Sweden due to declining codeine and/or tramadol use. Iceland had the highest opioid prevalence in 2009 (30.2%), increasing to 31.7% in 2018. In the same period, DIDs decreased in all five countries, and ranged from 28.3 in Finland to 58.5 in Denmark in 2009, and from 23.0 in Finland to 54.6 in Iceland in 2018. MMEs/user/day ranged from 4.4 in Iceland to 19.6 in Denmark in 2009, and from 4.6 in Iceland to 18.8 in Denmark in 2018. In Finland, Norway, and Sweden, MMEs/user/day increased from 2009 to 2018, mainly due to increasing oxycodone utilisation.

Conclusions

The stable or decreasing opioid utilisation prevalence among a majority of older adults across the Nordic countries coincides with an increase in treatment intensity in 2009–2018. We found large cross-national differences despite similarities across the countries’ cultures and healthcare systems. For the aged population, national efforts should be placed on improving pain management and monitoring future trends of especially oxycodone utilisation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Patel KV, Guralnik JM, Dansie EJ, Turk DC. Prevalence and impact of pain among older adults in the United States: findings from the 2011 National Health and aging trends study. Pain. 2013;154(12):2649–57.CrossRef Patel KV, Guralnik JM, Dansie EJ, Turk DC. Prevalence and impact of pain among older adults in the United States: findings from the 2011 National Health and aging trends study. Pain. 2013;154(12):2649–57.CrossRef
6.
go back to reference Pokela N, Bell JS, Lihavainen K, Sulkava R, Hartikainen S. Analgesic use among community-dwelling people aged 75 years and older: a population-based interview study. Am J Geriatr Pharmacother. 2010;8:233–44.CrossRef Pokela N, Bell JS, Lihavainen K, Sulkava R, Hartikainen S. Analgesic use among community-dwelling people aged 75 years and older: a population-based interview study. Am J Geriatr Pharmacother. 2010;8:233–44.CrossRef
9.
go back to reference Busse JW, Craigie S, Juurlink DN, Buckley DN, Li W, Couban RJ, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189:E659–66.CrossRef Busse JW, Craigie S, Juurlink DN, Buckley DN, Li W, Couban RJ, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189:E659–66.CrossRef
12.
go back to reference Prommer E, Ficek B. Management of pain in the elderly at the end of life. Drugs Aging. 2012;29(4):285–305.CrossRef Prommer E, Ficek B. Management of pain in the elderly at the end of life. Drugs Aging. 2012;29(4):285–305.CrossRef
16.
go back to reference Ping F, Wang Y, Wang J, Chen J, Zhang W, et al. Opioids increase hip fracture risk: a meta-analysis. J Bone Miner Metab. 2016;35(3):289–97.CrossRef Ping F, Wang Y, Wang J, Chen J, Zhang W, et al. Opioids increase hip fracture risk: a meta-analysis. J Bone Miner Metab. 2016;35(3):289–97.CrossRef
18.
go back to reference Häuser W, Petzke F, Radbruch L, Tölle TR. The opioid epidemic and the long-term opioid therapy for chronic noncancer pain revisited: a transatlantic perspective. Pain Manag. 2016;6(3):249–63.CrossRef Häuser W, Petzke F, Radbruch L, Tölle TR. The opioid epidemic and the long-term opioid therapy for chronic noncancer pain revisited: a transatlantic perspective. Pain Manag. 2016;6(3):249–63.CrossRef
20.
go back to reference Kristensen KB, Karlstad Ø, Martikainen JE, Pottegård A, Wastesson JW, Zoega H, et al. Nonaspirin nonsteroidal Antiinflammatory drug use in the Nordic countries from a cardiovascular risk perspective, 2000–2016: a drug utilization study. Pharmacotherapy. 2019;39:150–60. https://doi.org/10.1002/phar.2217.CrossRefPubMed Kristensen KB, Karlstad Ø, Martikainen JE, Pottegård A, Wastesson JW, Zoega H, et al. Nonaspirin nonsteroidal Antiinflammatory drug use in the Nordic countries from a cardiovascular risk perspective, 2000–2016: a drug utilization study. Pharmacotherapy. 2019;39:150–60. https://​doi.​org/​10.​1002/​phar.​2217.CrossRefPubMed
23.
go back to reference Bäckryd E, Heilig M, Hoffmann M. Opioid prescription changes in Sweden 2000–2015. Lakartidningen. 2017;114:EFUE.PubMed Bäckryd E, Heilig M, Hoffmann M. Opioid prescription changes in Sweden 2000–2015. Lakartidningen. 2017;114:EFUE.PubMed
31.
36.
go back to reference World Health Organization. Cancer pain relief: with a guide to opioid availability. 2nd ed. Geneva: World Health Organization; 1996. World Health Organization. Cancer pain relief: with a guide to opioid availability. 2nd ed. Geneva: World Health Organization; 1996.
38.
go back to reference Schmidt M, Hallas J, Laursen M, Friis S. Data resource profile: Danish online drug use statistics (MEDSTAT). Int J Epidemiol. 2016;45:1401–1402G.CrossRef Schmidt M, Hallas J, Laursen M, Friis S. Data resource profile: Danish online drug use statistics (MEDSTAT). Int J Epidemiol. 2016;45:1401–1402G.CrossRef
43.
go back to reference Jarlbaek L. Opioid prescribing habits differ between Denmark, Sweden and Norway- and they change over time. Scand J Pain. 2019;19:491–9.CrossRef Jarlbaek L. Opioid prescribing habits differ between Denmark, Sweden and Norway- and they change over time. Scand J Pain. 2019;19:491–9.CrossRef
44.
go back to reference Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the United States: promises and perils. Pain. 2013;154 Suppl 1(0 1):S94–S100.CrossRef Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the United States: promises and perils. Pain. 2013;154 Suppl 1(0 1):S94–S100.CrossRef
46.
go back to reference Wightman R, Perrone J, Portelli I, Nelson L. Likeability and abuse liability of commonly prescribed opioids. J Med Toxicol. 2012;8(4):335–40.CrossRef Wightman R, Perrone J, Portelli I, Nelson L. Likeability and abuse liability of commonly prescribed opioids. J Med Toxicol. 2012;8(4):335–40.CrossRef
50.
go back to reference Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37–48.CrossRef Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37–48.CrossRef
51.
go back to reference Hamina A, Taipale H, Tanskanen A, Tolppanen A-M, Karttunen N, Pylkkänen L, et al. Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study. Pain. 2017;158:252–60.CrossRef Hamina A, Taipale H, Tanskanen A, Tolppanen A-M, Karttunen N, Pylkkänen L, et al. Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study. Pain. 2017;158:252–60.CrossRef
52.
go back to reference Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2 Suppl):S3–11.CrossRef Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2 Suppl):S3–11.CrossRef
59.
go back to reference Wastesson JW, Martikainen JE, Zoëga H, Schmidt M, Karlstad Ø, Pottegård A. Trends in use of paracetamol in the Nordic countries. Basic Clin Pharmacol Toxicol. 2018;123:301–7.CrossRef Wastesson JW, Martikainen JE, Zoëga H, Schmidt M, Karlstad Ø, Pottegård A. Trends in use of paracetamol in the Nordic countries. Basic Clin Pharmacol Toxicol. 2018;123:301–7.CrossRef
Metadata
Title
Prescription opioids among older adults: ten years of data across five countries
Authors
A. Hamina
A. E. Muller
T. Clausen
S. Skurtveit
M. Hesse
C. Tjagvad
B. Thylstrup
I. Odsbu
H. Zoega
H. L. Jónsdóttir
H. Taipale
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2022
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-022-03125-0

Other articles of this Issue 1/2022

BMC Geriatrics 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine